Código QR (código de barras bidimensional)

Experience with anti-B-cell therapy in the pathogenetic treatment of multiple sclerosis

One of the promising areas in the pathogenetic treatment of multiple sclerosis (MS) is anti-B-cell therapy using ocrelizumab, an anti-CD20 monoclonal antibody. The drug is indicated for primary progressive MS (PPMS), secondary progressive MS (SPMS) and exacerbations, and highly active MS.Objective:...

תיאור מלא

שמור ב:
Principais autores: O. V. Boyko, S. V. Petrov, N. Yu. Lashch, M. R. Guseva, A. N. Boyko
פורמט: Artigo
שפה:Russo
יצא לאור: IMA-PRESS LLC 2019-03-01
סדרה:Неврология, нейропсихиатрия, психосоматика
נושאים:
multiple sclerosis
anti-b-cell therapy
pathogenetic treatment
ocrelizumab
גישה מקוונת:https://nnp.ima-press.net/nnp/article/view/1047
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים